UY26459A1 - 3,4-dihidroquinazolinas 5,6-disustituidas - Google Patents

3,4-dihidroquinazolinas 5,6-disustituidas

Info

Publication number
UY26459A1
UY26459A1 UY26459A UY26459A UY26459A1 UY 26459 A1 UY26459 A1 UY 26459A1 UY 26459 A UY26459 A UY 26459A UY 26459 A UY26459 A UY 26459A UY 26459 A1 UY26459 A1 UY 26459A1
Authority
UY
Uruguay
Prior art keywords
formula
compound
patient
pharmaceutically acceptable
platelet count
Prior art date
Application number
UY26459A
Other languages
English (en)
Inventor
Philip C Lang
Original Assignee
Roberts Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roberts Lab Inc filed Critical Roberts Lab Inc
Publication of UY26459A1 publication Critical patent/UY26459A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se ha encontrado que los compuestos de fórmula (en donde X e Y, que pueden ser iguales o diferentes, que representan cada uno CI, Br o F) y tautómeros de los mismos, tienen mejores propiedades de reducción del recuento de plaquetas. También se proporcionan métodos para preparar sintéticamente los compuestos de fórmula (E) y sales de adición farmacéuticamente aceptables de los mismos y un método para reducir el recuento de plaquetas en un paciente mediante la administración al paciente de una cantidad efectiva reductora de plaquetas de un compuesto de fórmula (E) preferentemente junto con un portador farmacéuticamente aceptable. También se proporciona una composición farmacéutica que contiene un compuesto de fórmula (E) como ingrediente activo junto con excipientes farmacéuticamente acepables. Además se proporciona un compuesto de fórmula (E) para uso en terapia y el uso de un compuesto de fórmula (E) paraz preparar un medicamento para reducir el recuento de plaquetas en un paciente.
UY26459A 1999-11-30 2000-11-29 3,4-dihidroquinazolinas 5,6-disustituidas UY26459A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/452,008 US6194420B1 (en) 1999-11-30 1999-11-30 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
UY26459A1 true UY26459A1 (es) 2001-06-29

Family

ID=23794633

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26459A UY26459A1 (es) 1999-11-30 2000-11-29 3,4-dihidroquinazolinas 5,6-disustituidas

Country Status (6)

Country Link
US (1) US6194420B1 (es)
AR (1) AR026631A1 (es)
AU (1) AU1538101A (es)
CA (1) CA2392630C (es)
UY (1) UY26459A1 (es)
WO (1) WO2001040196A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10301105B4 (de) * 2003-01-09 2005-11-24 Chemisch-Pharmazeutisches Labor, Rolf Sachse Gmbh Verwendung von 2-Amino-2H-chinazolin-Derivaten zur Behandlung von myeloproliferativen Erkrankungen, Bluthochdruck und Bronchodilation
CA2513708C (en) * 2003-01-23 2011-01-04 Shire Holdings Ag Formulation and methods for the treatment of thrombocythemia
US20060030574A1 (en) 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
JP4769866B2 (ja) * 2005-06-27 2011-09-07 エフ．ホフマン−ラ ロシュ アーゲー クロロ置換グアニジン
US7910597B2 (en) * 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
US8304420B2 (en) * 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
GB0623749D0 (en) * 2006-11-28 2007-01-10 Shire Llc Substituted quinazolines
WO2019080982A1 (en) * 2017-10-26 2019-05-02 Osaa Innovation Aps APPARATUS FOR DISPENSING A LIQUID FROM A COMPRESSIBLE BAG

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2862966A (en) 1958-12-02 archo
USRE31617E (en) 1972-02-04 1984-06-26 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US3932407A (en) 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US4146718A (en) 1978-04-10 1979-03-27 Bristol-Myers Company Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
US4208521A (en) 1978-07-31 1980-06-17 Bristol-Myers Company Process for the preparation of imidazo[2,1-b]quinazolinones
US4357330A (en) 1981-07-30 1982-11-02 Bristol-Myers Company Pharmaceutical compositions
CA2171073A1 (en) * 1995-12-04 1997-06-05 Philip C. Lang Process for the preparation of ethyl-n-(2,3 dichloro-6- nitrobenzyl) glycine

Also Published As

Publication number Publication date
CA2392630A1 (en) 2001-06-07
AR026631A1 (es) 2003-02-19
CA2392630C (en) 2010-01-26
WO2001040196A1 (en) 2001-06-07
AU1538101A (en) 2001-06-12
US6194420B1 (en) 2001-02-27

Similar Documents

Publication Publication Date Title
NO20060974L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
ECSP066314A (es) Derivados piridilo y su uso como agentes terapéuticos
GEP20053673B (en) Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
TNSN06034A1 (en) Pyridazine derivatives and their use as therapeutic agents
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
CR9662A (es) Ingrediente farmaceutico canabinoide activo para formas de dosis mejoradas
AR052198A1 (es) Formulaciones anticuerpo anti a beta
MY141939A (en) Pyridazine derivatives and their use as therapeutic agents
BR0211228A (pt) Composto, composição farmacêutica e seus usos
SE9901573D0 (sv) New compounds
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
AR033688A1 (es) Composicion parenteral reconstituible
SE9900961D0 (sv) Novel compounds
AR043822A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
UY26459A1 (es) 3,4-dihidroquinazolinas 5,6-disustituidas
SE0002476D0 (sv) New compounds
UA83832C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и их применение
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
NO912414L (no) Forbindelse med mavesyreinhiberende effekt og fremgangsmaate for dens fremstilling.
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE9901572D0 (sv) New compounds

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20130204